NASDAQ
07.01.26 | 19:56
1,110 US-Dollar
-5,13 % -0,060
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders | 65 | PR Newswire | Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design... ► Artikel lesen | |
| 30.12.25 | Evogene appoints Dr. Olga Nissan as VP of business development | 2 | Investing.com | ||
| 30.12.25 | Evogene ernennt Dr. Olga Nissan zur Vice President für Geschäftsentwicklung | 3 | Investing.com Deutsch | ||
| 30.12.25 | Evogene Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.11.25 | Evogene übertrifft Gewinnerwartungen nach Restrukturierung trotz Umsatzrückgangs | 2 | Investing.com Deutsch | ||
| EVOGENE Aktie jetzt für 0€ handeln | |||||
| 20.11.25 | Evogene: EPS übertrifft Schätzungen um 0,12 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 20.11.25 | Evogene GAAP EPS of -$0.31 beats by $0.10, revenue of $0.31M misses by $0.34M | 2 | Seeking Alpha | ||
| 20.11.25 | Evogene Reports Third Quarter 2025 Financial Results | 99 | PR Newswire | Conference call and webcast: today, November 20, 2025, 9:00 AM ET
Financial Highlights:
During the first nine months ending September 30, 2025, Evogene advanced... ► Artikel lesen | |
| 20.11.25 | Evogene Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.11.25 | Evogene Q3 2025 Earnings Preview | 1 | Seeking Alpha | ||
| 19.11.25 | What's Next: Evogene's Earnings Preview | 1 | Benzinga.com | ||
| 30.09.25 | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09.25 | Evogene Ltd. - 6-K, Report of foreign issuer | 10 | SEC Filings | ||
| 19.08.25 | Evogene Q2 2025: Kostensenkungen federn verfehlte Umsatz- und Gewinnziele ab | 3 | Investing.com Deutsch | ||
| 19.08.25 | Evogene GAAP EPS of -$0.85 misses by $0.22, revenue of $0.88M misses by $0.05M | 1 | Seeking Alpha | ||
| 19.08.25 | Evogene Reports Second Quarter 2025 Financial Results | 165 | PR Newswire | Conference call and webcast: today, August 19, 2025, 9:00 am ET
Financial Highlights:
The financial results for the first half of 2025 of Lavie Bio, a subsidiary... ► Artikel lesen | |
| 18.08.25 | Evogene Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.08.25 | Preview: Evogene's Earnings | 1 | Benzinga.com | ||
| 12.08.25 | Evogene startet KI-gestützte Forschungskooperation mit Universität Tel Aviv zur Behandlung von Stoffwechselerkrankungen | 2 | Investing.com Deutsch | ||
| 12.08.25 | Evogene partners with Tel Aviv University to develop metabolic disease treatments | 2 | Investing.com |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,70 | -0,06 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| QIAGEN | 40,245 | +0,65 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| CUREVAC | 3,930 | -0,05 % | XFRA 5CV: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCUREVAC N.V. O.N.... ► Artikel lesen | |
| MODERNA | 30,760 | +0,05 % | MODERNA: Heute ein Exot dank Impfstoff-Fortschritt. | Das Biotech-Unternehmen schafft heute eine Performance von aktuell + 9,7 %. Abgesehen vom zweiten "Exoten" AXON (+ 6,0 %), wird das Feld Top 10 klar von Halbleiter-Werten dominiert. Für den Antrieb... ► Artikel lesen | |
| STRYKER | 314,30 | -0,13 % | VB Spine LLC: VB Spine Completes Acquisition of Cestas Manufacturing Facility from Stryker | Deal expands global manufacturing footprint and positions VB Spine for future growth in spine care VB Spine LLC ("VB Spine") today completed the acquisition of Stryker's spine implant manufacturing... ► Artikel lesen | |
| BIOGEN | 159,85 | -0,16 % | Mizuho hebt Kursziel für Biogen auf 207 Dollar an und verweist auf verbesserte Aussichten für 2026 | ||
| CRISPR THERAPEUTICS | 50,000 | +0,40 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 695,80 | 0,00 % | Regeneron Just Moved From Underperform To Buy - Here's Why | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer | SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,450 | +0,69 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,397 | +0,28 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| INFLARX | 1,000 | -3,15 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,770 | +1,15 % | Intellia Stock Declines Around 55% in 3 Months: Here's Why | ||
| EDITAS MEDICINE | 1,865 | +1,06 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen |
EVOGENE LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -5,13 % bei einem Aktienkurs von 1,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOGENE LTD finden Sie auf Wallstreet Online.